TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
TG Therapeutics, Inc. (
NASDAQ: TGTX), today announced the schedule of upcoming presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to as MSToronto2026, being held October 21-23, 2026, in Toronto, Canada. The presentations include a late-breaking oral presentation highlighting initial results from a Phase 1 study evaluating azer-cel in patients with primary progressive multiple sclerosis (PPMS), as well as several presentations highlighting BRIUMVI® (ublituximab-xiiy) across clinical trials and real-world settings in multiple sclerosis (MS).
